Skip to main content

Venture Capital Firm  I  Home

Innovation.
Clarity.
Execution.

A Venture Capital Firm for Visionary Innovators.

Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.

We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.

We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
About

As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.

We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.
Team

Innovation.

We are backing exceptional innovation early.

Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.

As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.

Portfolio

Latest Press Releases

14 January 2025 in Pheno Therapeutics, Press Release, Private Companies

Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802

Press Release.   Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802 UK MHRA grants CTA for first-in-human trial of a selective GPR17 antagonist Small molecule…
Read More
13 January 2025 in Press Release, Private Companies, Rappta Therapeutics

Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A 

Press Release.   Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A  Goal to accelerate development and commercialization of the…
Read More
9 January 2025 in Advent Life Sciences, Press Release

Relief Cardiovascular Announces $12M Series A Financing to Advance First-in-Human Study of the Relief System

Press Release.   Relief Cardiovascular Announces $12M Series A Financing to Advance First-in-Human Study of the Relief System Irvine, California – January 8, 2025 – Relief Cardiovascular, an inQB8 Medical…
Read More

About

Leading Venture Investors
Learn More

Portfolio

Innovative Life Sciences Companies
Learn More